Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Tana Takacova posted on LinkedIn

Revumenib Shows Promise in Acute Leukemia - CancerConnect

The menin inhibitor revumenib in KMT2A-rearranged or NPM1

Revumenib: a new therapy for AML patients

PDF) Therapeutic targeting of leukemia stem cells in acute myeloid

JCM, Free Full-Text

NRG1 Fusions Hold Promise as Pan-tumor Target

Revumenib Shows Promise in Acute Leukemia - CancerConnect

Research Areas: Treatment - NCI

Clinical Trial Results National Cancer Institute

Treatment - Cancer Currents Blog - NCI

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

Treatment National Cancer Institute

Rekha Rao Manepalli, Ph.D, SMBA on LinkedIn: Revumenib Shows

Drug 'cures' 33% of patients with aggressive leukaemia in early